Drug makers aren't chasing blockbusters like Lipitor anymore, or uncovering compounds the same way.

A new approach to phenotype assessment is the holy grail for today's medical scientists.

The evolution of the European Union"s approach to regulating biosimilars is a potential model upon which we can design a process that facilitates access to biosimilars while providing assurances of safety.

Regardless of the intentions, clinical drug trials driven primarily by marketing yield enormous benefits for patients and practitioners.

How many veterans fall through the gap between care and compensation is a question that is worth investigating. The scope is important, but there is little question that the problem exists.

Reducing end-of-life costs will do little to curb the growth in Medicare spending overall. But end-of-life care provision should be reformed to match the values of patients.

If a new comparative effectiveness research agency is allowed to use different--or inferior--scientific standards than those imposed on the private sector, the government will be the only voice in CER.

Repealing the Patient Protection and Affordable Care Act will not be enough, for a simple reason: Although Obamacare would worsen many of the problems with our system of health-care financing, that system clearly does call out for serious reform.